Sharda Cropchem Limited has informed the Exchange about Transcript

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDF

SHARDACROP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-0.3%1-day move

₹895.00

prior close

₹917.00

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.2+0.3-0.2-0.3+1.0-0.3+5.9+8.0+0.6+0.1+0.7-1.1—

Up moveDown movePending

AI summary

Sharda Cropchem reported its best-ever financial year in FY26 with Q4 revenues of INR 2,065 crore (up 13% YoY) and full-year revenues of INR 5,268 crore (up 22%). PAT grew 124% to INR 681 crore for the full year, while EBITDA reached INR 1,040 crore with 69% growth. The company expanded gross margins by 750 basis points to 37.3% in Q4. Management guided for FY27 revenue growth of 10-15%, gross margins around 35%, and EBITDA margins of 18-20%. The company remains debt-free with INR 702 crore in cash as of March 31, 2026. Total product registrations stood at 3,011 with 1,004 applications in pipeline. Volume growth in Q4 was 4.3% with FX contributing 11.7% to revenue growth.

Likely market impact

The company delivered exceptional results driven by margin expansion and FX benefits. The guidance for FY27 indicates continued but more moderate growth with some normalization in margins. The strong cash position and debt-free status provide financial flexibility.